Tevimbra Approved in Combination with Chemotherapy as First-Line Treatment for a Type of Gastric Cancer
BeiGene has announced that the U.S. Food and Drug Administration (FDA) has approved Tevimbra (tislelizumab), a PD-1 protein inhibitor, in combination with chemotherapy as a first-line treatment for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
This approval expands Tevimbra’s indication in the U.S., where it was previously approved for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma.
